Message from the Top Management
The pharmaceutical industry is passing through a very challenging phase. Currently, theindustry is facing head wind on account of several domestic and international factors.Most of these factors are dynamic by their very nature and demand considerable time,energy and efforts to overcome them. Indoco today, is better prepared to meet thesechallenges and has the necessary infrastructure and skill sets in place. The 'Innovationin Quality Excellence Award' received from UBM at the CPhl India 2012 is a recognition ofthe robust systems and practices followed by the Company.
Your Company has achieved a turnover of Rs. 4070.2 million in the domestic business andRs. 2187.1 million in the international business in the financial year 2012-13. During theyear, 37 products have been launched in the domestic market, across acute and chronictherapies. Moving forward, the Company has plans to increase the share of the chronicsegment while continuing to promote legacy brands.
In the international markets, the alliances and partnership model will bring synergythrough optimum utilization of the Company's and partners' strengths and competencies. TheUS business is set to take off and speedily ramp up upon AN DA approvals by USFDA. TheCompany is moving from contract manufacturing to 'supplies against own dossiers/marketingauthorizations' in European markets and concrete steps in that direction have been taken.
A formal plan is in place to achieve an ambitious target for the coming years and theCompany is confident of achieving the same. We express our gratitude to all ourstakeholders including shareholders, customers, bankers, vendors and the medicalfraternity for their unstinted support. We thank all Indocoiites for their contributionwhich we value the most.
Thanking you all!
Suresh G. Kare
|Aditi Panandikar ||Sundeep V. Bambolkar |
|Managing Director ||Jt. Managing Director |